Medico-pharmaceutical law: Difference between revisions
Initial source-linked scientific wiki setup |
Expand source-linked scientific reference and navigation |
||
| Line 1: | Line 1: | ||
'''Medico-pharmaceutical law''' is used in this research programme for an integrated approach to healthcare, medicines and their governance. Related publications also use the wording '''medical and pharmaceutical law'''. These expressions should be explained in their source-specific context rather than assumed to be perfectly interchangeable across every author or jurisdiction. | |||
=== Development in the publications === | |||
Shapovalova's article, posted online in 2021 in an issue labelled 2020, distinguishes the field as legal norms, scientific knowledge, and legislation. Its framework brings together medicine regulation, evidence-based practice, forensic pharmacy and professional legal relationships.<ref>V.O. Shapovalova. [https://apmplmi.com/index.php/apmp/article/view/12 System of drugs circulation based on medical and pharmaceutical law]. 1(1–2), issue labelled 2020; website publication date 26 April 2021.</ref> | |||
A 2025 editorial by Ivan Voloshyn-Haponov, Valerii Shapovalov, Andrii Diachenko and Natalia Matsko explicitly advocates combining medical and pharmaceutical law. It describes a body of norms governing healthcare and pharmaceutical activities, including medicines circulation. This is an attributed scholarly proposal, not evidence that a new universally recognized statutory branch has been enacted.<ref>[https://ssp.sreif.us/index.php/mlp/article/view/6 Forensic Pharmaceutical Studies of the Level of Illicit Trafficking of Psychoactive Substances: Drug Addiction Among Minors and Youth, Consequences for Mental Public Health and Need for Rehabilitation Activities]. SSP Modern Law and Practice 5(3), 1–30, 14 July 2025. DOI:10.53933/qn4b7s67.</ref> | |||
In ''Vision 2035 – Medico-Pharmaceutical Law for Human Security'' (2026), the authors extend the approach into a multi-region governance project. The six proposed pillars are patient rights, quality and safety, data and evidence, supply security, accountability, and equitable access. The proposal also considers clinical AI and resilient medicine supplies. These are programme objectives, not independently demonstrated outcomes.<ref>[https://books.sreif.us/index.php/sreif/catalog/book/13 Vision 2035 – Medico-Pharmaceutical Law for Human Security]. Valentyn Shapovalov, Viktoriia Shapovalova, Valerii Shapovalov, Oleksandr Veits, Andrii Diachenko and Alina Osyntseva. Published 6 March 2026. DOI:10.53933/b91avw28. ISBN 979-8-9942371-3-7.</ref> | |||
=== How to read the concept === | |||
Its practical value as an organizing framework is that it encourages readers to consider several connected responsibilities together. For example, an analysis of medicine access can examine the treatment decision, product quality, availability, affordability and routes for redress without treating these as unrelated subjects. A wiki explanation should nevertheless distinguish descriptive scholarship, reform proposals and binding law. | |||
== References == | |||
<references /> | |||
[[Category:Scientific concepts]] | |||
See also: [[Terms and concepts|Terms and concepts index]] · [[Journal research map]] · [[History and research foundations]]. | |||
Revision as of 23:31, 11 November 2026
Medico-pharmaceutical law is used in this research programme for an integrated approach to healthcare, medicines and their governance. Related publications also use the wording medical and pharmaceutical law. These expressions should be explained in their source-specific context rather than assumed to be perfectly interchangeable across every author or jurisdiction.
Development in the publications
Shapovalova's article, posted online in 2021 in an issue labelled 2020, distinguishes the field as legal norms, scientific knowledge, and legislation. Its framework brings together medicine regulation, evidence-based practice, forensic pharmacy and professional legal relationships.[1]
A 2025 editorial by Ivan Voloshyn-Haponov, Valerii Shapovalov, Andrii Diachenko and Natalia Matsko explicitly advocates combining medical and pharmaceutical law. It describes a body of norms governing healthcare and pharmaceutical activities, including medicines circulation. This is an attributed scholarly proposal, not evidence that a new universally recognized statutory branch has been enacted.[2]
In Vision 2035 – Medico-Pharmaceutical Law for Human Security (2026), the authors extend the approach into a multi-region governance project. The six proposed pillars are patient rights, quality and safety, data and evidence, supply security, accountability, and equitable access. The proposal also considers clinical AI and resilient medicine supplies. These are programme objectives, not independently demonstrated outcomes.[3]
How to read the concept
Its practical value as an organizing framework is that it encourages readers to consider several connected responsibilities together. For example, an analysis of medicine access can examine the treatment decision, product quality, availability, affordability and routes for redress without treating these as unrelated subjects. A wiki explanation should nevertheless distinguish descriptive scholarship, reform proposals and binding law.
References
- ↑ V.O. Shapovalova. System of drugs circulation based on medical and pharmaceutical law. 1(1–2), issue labelled 2020; website publication date 26 April 2021.
- ↑ Forensic Pharmaceutical Studies of the Level of Illicit Trafficking of Psychoactive Substances: Drug Addiction Among Minors and Youth, Consequences for Mental Public Health and Need for Rehabilitation Activities. SSP Modern Law and Practice 5(3), 1–30, 14 July 2025. DOI:10.53933/qn4b7s67.
- ↑ Vision 2035 – Medico-Pharmaceutical Law for Human Security. Valentyn Shapovalov, Viktoriia Shapovalova, Valerii Shapovalov, Oleksandr Veits, Andrii Diachenko and Alina Osyntseva. Published 6 March 2026. DOI:10.53933/b91avw28. ISBN 979-8-9942371-3-7.
See also: Terms and concepts index · Journal research map · History and research foundations.